title: Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?
authors.forename: Enrico
authors.initials: E
authors.lastname: Franceschi
authors.forename: Alba A
authors.initials: AA
authors.lastname: Brandes
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology*; D000068258:Bevacizumab; D016503:Drug Delivery Systems; D005909:Glioblastoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009364:Neoplasm Recurrence, Local; D011859:Radiography; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab